OSAplex MK-7 By XYMOGEN Overview & Drug Interactions

Check For Interactions With OSAplex MK-7

Supplement: OSAplex MK-7 by XYMOGEN

OSAplex MK-7 Label Images

This product contains

Below is a list of the 'active' ingredients listed on the supplement label for this product.

For a list of 'other ingredients', such as fillers, please see the 'Label Information' section on this page.

Drugs that interact with OSAplex MK-7 by XYMOGEN

Below is a list of drug interactions for each ingredient in this supplement product. Please note that a supplement product may contain more than one ingredient that has interactions.

Label Information

Supplement Facts:

Daily Value (DV) Target Group(s): Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
1 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
1 Capsule(s)
Servings per container 60
UPC/BARCODE 871149003630

Ingredient Amount per Serving Group % DV, Adults & children 4+ years
Vitamin D3
1000 IU
Vitamin D 250%
Vitamin K2
45 mcg
Vitamin K (menaquinone) 56%
Calcium
550 mg
Calcium 55%
Phosphorus
198 mg
Phosphorus 20%
MCHC
2.2 Gram(s)
Calcium --
Microcrystalline Hydroxyapatite
1.32 Gram(s)
Calcium --
Choline
60 mg
Choline --
Silicon
3 mg
Silicon --

Other Ingredients:
HPMC
Stearic Acid
Vegetable Magnesium Stearate
Medium-Chain Triglycerides
Silica
Other Ingredients for ch-OSA Capsule
Forms
  • HPMC
  • Microcrystalline Cellulose
  • purified Water


Label Statments:


General Statements
- Professional Use Only
- OSAplex MK-7 is a comprehensive, convenient, and cost-effective dietary supplement that supports healthy bones, cartilage, and ligaments.
- Bone is composed of a calcium-based mineral complex and an organic material known as collagen. A somewhat flexible and fibrous protein, collagen appears to be a key factor in a bone's ability to withstand sudden impact. The quantity and health of collagen determines the bone's "toughness", while the mineral content determines its strength and stiffness.
- Silicon-dependent enzymes link together single chains of amino acids to synthesize collagen fibers. The surfaces of these collagen fibers act as the binding sites for the MCHC. The more surface area available tot he MCHC to bind to, the more flexible the bone.
- Supports overall bone health and strength
- ePV:
- Exclusive professional formulas
- Microcrystalline hydroxyapatite concentrate
- Scan To Learn More!
- This package is completely recyclable
Brand IP Statement(s)
- Not for resale on third-party websites, including, but not limited to, Amazon and eBay.
- Choline-stabilized orthosilicic acid (ch-OSA) is a registered trademark of and manufactured by Bio Minerals n.v., Belgium. Produced under US patents 5,922,360; 7,968,528; and 8,771,757.
- VitaMK7 is a trademark of Gnosis S.p.A.
- 2016 XYMOGEN
Suggested/Recommended/Usage/Directions
- Directions: Consume the contents of one packet with a meal, one to two times daily, or as directed by your healthcare practitioner.
Precautions
- Consult your healthcare practitioner prior to use.
- Individuals taking medication should discuss potential interactions with their healthcare practitioner. Consider total vitamin K intake (food + supplements) if you are taking blood-thinning medications. Present studies show that 45 mcg of MK-7 from VitaMK7 daily is not likely to interfere with blood-thinning medicines.
- Do not use if tamper seal is damaged.
- Storage: Keep closed in a cool, dry place out of reach of children.
Formulation
- The labeling on this product does not comply with California's Proposition 65. Therefore, this product may not be sold in California.
- Does not contain: Wheat, gluten, yeast, soy protein, dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.
Formula
- Each packet provides the following: two capsules containing a combination of microcrystalline hydroxyapatite concentrate (MCHC) from Ossopan 1100, vitamin D3, and vitamin K2 along with one capsule of choline-stabilized orthosilicic acid (ch-OSA).
- OSAplex MK-7 contains choline-stabilized orthosilicic acid, a well-absorbed form of silicon that has been clinically tested.
- MCHC, a proprietary, standardized, safe-source bone extract from New Zealand bovine, contains a crystalline calcium and phosphorus matrix in the ideal physiological ratio of 2:1, plus bioactive growth factors and type I collagen. As a source of calcium, MCHC contributes to the production and maintenance of bone structure, a function supported by vitamin D3 and K2. Amino acids, glycosaminoglycans, and a broad range of essential trace elements are also present. Combine ch-OSA and MCHC with significant levels of vitamin D3 and K2, and the result is a unique package that addresses quantity and quality of bone, and supports overall bone strength and health.
FDA Disclaimer Statement
- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Storage
- Storage: Keep closed in a cool, dry place out of reach of children.
FDA Statement of Identity
- Dietary Supplement
Seals/Symbols
- GMP Compliant Third-Party Verified
- Vegetarian Caps
General
- ZLB-OSAMK7-05 REV. 031516

Brand Information

See all products by this brand

Manufacturer
Name XYMOGEN Exclusive Professional Formulas
Street Address 6900 Kingspointe Pkwy.
City Orlando
State FL
ZipCode 32819
Phone Number 800-647-6100
Web Address www.xymogen.com

Return to the main supplement interaction checker page

Parts of this content are provided by the Therapeutic Research Center, LLC and the Dietary Supplement Label Database.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Drug descriptions are provided by MedlinePlus.